REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 174 filers reported holding REATA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $34,747,254 | +12.1% | 340,793 | 0.0% | 0.15% | +17.3% |
| Q1 2023 | $30,984,900 | +139.3% | 340,793 | 0.0% | 0.13% | +159.2% |
| Q4 2022 | $12,946,726 | +151076.2% | 340,793 | 0.0% | 0.05% | +53.1% |
| Q3 2022 | $8,564 | -99.9% | 340,793 | 0.0% | 0.03% | -5.9% |
| Q2 2022 | $10,357,000 | -7.2% | 340,793 | 0.0% | 0.03% | +21.4% |
| Q1 2022 | $11,164,000 | +24.2% | 340,793 | 0.0% | 0.03% | +21.7% |
| Q4 2021 | $8,987,000 | -73.8% | 340,793 | 0.0% | 0.02% | -69.7% |
| Q3 2021 | $34,287,000 | -28.9% | 340,793 | 0.0% | 0.08% | -30.3% |
| Q2 2021 | $48,232,000 | +42.0% | 340,793 | 0.0% | 0.11% | +60.3% |
| Q1 2021 | $33,977,000 | -19.4% | 340,793 | 0.0% | 0.07% | -54.1% |
| Q4 2020 | $42,129,000 | +81.3% | 340,793 | +42.9% | 0.15% | +64.4% |
| Q3 2020 | $23,240,000 | -46.6% | 238,555 | -14.5% | 0.09% | -51.1% |
| Q2 2020 | $43,543,000 | – | 279,085 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |